The Company recently entered into an exclusive worldwide licensing agreement with Giiant Pharma, Inc. for multiple oral drug candidates targeting inflammatory bowel disease (IBD) and a proprietary precision delivery technology platform. IBD represents a multi-billion-dollar market opportunity in need of innovative approaches, with current therapies achieving a clinical remission rate of less than 20% on average.
Palisade Bio’s lead program, GT-2108 is a microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis and is advancing toward the completion of IND-enabling studies and an IND filing. The Company’s second lead program, GT-1908, is being evaluated in preclinical development for the treatment of fibro stenotic Crohn’s Disease.
Our leadership is comprised of a team of experts in clinical development, commercialization, and pipeline development who are passionate about the advancement of science and medicine.
Board Of Directors
Clinical Steering Committee
Scientific Advisory Board
The Palisade Bio team is dedicated to identifying and developing new therapies for a range of serious, widespread health conditions that impact millions of patients every year. We are driven by science—and supported by a culture of innovation, openness and problem-solving.
Join us in our mission.